MDS Pharma Services
Phoenix, Arizona, United States
NCT Number: NCT01616485
The objective of this study is to evaluate the hemodynamic response to a sublingual dose of glyceryl trinitrate in subjects receiving oral TA-1790, sildenafil citrate, and placebo.
Looking for future studies?
Notify Me30 year–60 year
Male
Interventional
Phase 1
Phoenix, Arizona, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
2 TA-1790 100 mg capsules
2 sildenafil citrate 50 mg capsules
2 placebo capsules for TA-1790 100 mg capsules
glyceryl trinitrate tablet, USP 0.4 mg
Time frame: Pre-dose, 5 min interval for first 45 minutes. 60, 90, and 120 minutes post-dose.
Change in hemodynamic measurements consisted of blood pressure and pulse rate measurements.
VIVUS LLC
Industry
A Double-blind, Randomized, Crossover Evaluation of the Hemodynamic Response to Sublingual Glyceryl Trinitrate in Patients Receiving TA-1790, Sildenafil, and Placebo
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07715448
Benign Prostatic Hyperplasia, Ejaculatory Dysfunction
Banī Suwayf, Beni Suef Governorate, Egypt
View Trial DetailsNCT06805513
Erectile Dysfunction, Genital Diseases
Salt Lake City, Utah, United States
View Trial DetailsNCT07692867
Erectile Dysfunction, Genital Diseases
Beijing, China
View Trial DetailsNCT07460167
Erectile Dysfunction, Genital Diseases
Qina, Egypt
View Trial Details